Walla Katharina, Habenbacher Michael, Kay Janina, Walrave Laura, Günzl Philipp, Tomazic Peter Valentin, Andrianakis Alexandros
Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria.
GlaxoSmithKline, Vienna, Austria.
Sci Rep. 2025 Jul 2;15(1):23051. doi: 10.1038/s41598-025-07658-3.
This article aims to describe the current diagnostic and therapeutic practices for managing chronic rhinosinusitis with nasal polyps (CRSwNP) among Austrian ENT specialists. A cross-sectional, nationwide survey was conducted between November and December 2022 in Austria. A total of 50 ENT specialists, evenly split between hospital- and office-based physicians, participated. The questionnaire covered demographics, diagnostic and therapeutic approaches. CT imaging, nasal endoscopy, and blood eosinophil count were the most utilized diagnostic tools. Most participants applied the SNOT-22 for patient-reported outcomes. Local corticosteroids were the most frequently prescribed treatment. Systemic corticosteroid overuse and limited biologic adoption were noted. Hospital-based physicians managed significantly more patients with biologics. The initiation of biologic therapy was considered most appropriate following one FESS by the vast majority of respondents. Adherence to guideline-based evaluation criteria for biologic treatment response was suboptimal, highlighting gaps in clinical practice. Our survey highlights strengths in guideline adherence and areas for improvement, particularly in the diagnostic approach, systemic corticosteroid usage, and biologic treatment. Addressing educational gaps and refining clinical practices could enhance patient outcomes, reduce invasive procedures, and optimize resource utilization in CRSwNP management.
本文旨在描述奥地利耳鼻喉科专家对伴鼻息肉的慢性鼻-鼻窦炎(CRSwNP)的当前诊断和治疗方法。2022年11月至12月在奥地利进行了一项全国性横断面调查。共有50名耳鼻喉科专家参与,其中医院医生和门诊医生各占一半。问卷涵盖人口统计学、诊断和治疗方法。CT成像、鼻内镜检查和血液嗜酸性粒细胞计数是最常用的诊断工具。大多数参与者使用SNOT-22来评估患者报告的结果。局部糖皮质激素是最常用的治疗药物。存在全身糖皮质激素过度使用和生物制剂应用受限的情况。医院医生治疗使用生物制剂的患者明显更多。绝大多数受访者认为在一次功能性鼻内镜鼻窦手术(FESS)后开始生物治疗最为合适。对生物治疗反应的基于指南的评估标准的依从性欠佳,凸显了临床实践中的差距。我们的调查突出了在遵循指南方面的优势以及需要改进的领域,特别是在诊断方法、全身糖皮质激素使用和生物治疗方面。弥补教育差距并完善临床实践可以改善CRSwNP管理中的患者预后、减少侵入性手术并优化资源利用。